Skip to main content
Top
Published in: Diabetologia 2/2012

01-02-2012 | Article

A metabolomic study of low estimated GFR in non-proteinuric type 2 diabetes mellitus

Authors: D. P. K. Ng, A. Salim, Y. Liu, L. Zou, F. G. Xu, S. Huang, H. Leong, C. N. Ong

Published in: Diabetologia | Issue 2/2012

Login to get access

Abstract

Aims/hypothesis

We carried out a urinary metabolomic study to gain insight into low estimated GFR (eGFR) in patients with non-proteinuric type 2 diabetes.

Methods

Patients were identified as being non-proteinuric using multiple urinalyses. Cases (n = 44) with low eGFR and controls (n = 46) had eGFR values <60 and ≥60 ml min−1 1.73 m−2, respectively, as calculated using the Modification of Diet in Renal Disease formula. Urine samples were analysed by liquid chromatography/mass spectrometry (LC/MS) and GC/MS. False discovery rates were used to adjust for multiple hypotheses testing, and selection of metabolites that best predicted low eGFR status was achieved using least absolute shrinkage and selection operator logistic regression.

Results

Eleven GC/MS metabolites were strongly associated with low eGFR after correction for multiple hypotheses testing (smallest adjusted p value = 2.62 × 10−14, largest adjusted p value = 3.84 × 10−2). In regression analysis, octanol, oxalic acid, phosphoric acid, benzamide, creatinine, 3,5-dimethoxymandelic amide and N-acetylglutamine were selected as the best subset for prediction and allowed excellent classification of low eGFR (AUC = 0.996). In LC/MS, 19 metabolites remained significant after multiple hypotheses testing had been taken into account (smallest adjusted p value = 2.04 × 10−4, largest adjusted p value = 4.48 × 10−2), and several metabolites showed stronger evidence of association relative to the uraemic toxin, indoxyl sulphate (adjusted p value = 3.03 × 10−2). The potential effect of confounding on the association between metabolites was excluded.

Conclusions/interpretation

Our study has yielded substantial new insight into low eGFR and provided a collection of potential urinary biomarkers for its detection.
Appendix
Available only for authorised users
Literature
1.
go back to reference Kramer CK, Leitão CB, Pinto LC, Silveiro SP, Gross JL, Canani LH (2007) Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 30:1998–2000PubMedCrossRef Kramer CK, Leitão CB, Pinto LC, Silveiro SP, Gross JL, Canani LH (2007) Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 30:1998–2000PubMedCrossRef
2.
go back to reference Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, Study Group UKPDS (2006) Risk factors for renal dysfunction in type 2 diabetes. UKPDS 74. Diabetes 55:1832–1839PubMedCrossRef Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR, Study Group UKPDS (2006) Risk factors for renal dysfunction in type 2 diabetes. UKPDS 74. Diabetes 55:1832–1839PubMedCrossRef
3.
go back to reference MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G (2004) Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27:195–200PubMedCrossRef MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G (2004) Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27:195–200PubMedCrossRef
4.
go back to reference MacIsaac RJ, Panagiotopoulos S, McNeil KJ et al (2006) Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 29:1560–1566PubMedCrossRef MacIsaac RJ, Panagiotopoulos S, McNeil KJ et al (2006) Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 29:1560–1566PubMedCrossRef
5.
go back to reference Niewczas MA, Ficociello LH, Johnson AC et al (2009) Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 4:62–70PubMedCrossRef Niewczas MA, Ficociello LH, Johnson AC et al (2009) Serum concentrations of markers of TNFalpha and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 4:62–70PubMedCrossRef
6.
go back to reference Weckwerth W, Morgenthal K (2005) Metabolomics: from pattern recognition to biological interpretation. Drug Discov Today 10:1551–1558PubMedCrossRef Weckwerth W, Morgenthal K (2005) Metabolomics: from pattern recognition to biological interpretation. Drug Discov Today 10:1551–1558PubMedCrossRef
7.
go back to reference Niwa T (2009) Recent progress in the analysis of uremic toxins by mass spectrometry. J Chrom B 877:2600–2606CrossRef Niwa T (2009) Recent progress in the analysis of uremic toxins by mass spectrometry. J Chrom B 877:2600–2606CrossRef
8.
go back to reference Koulman A, Lane GA, Harrison SJ (2009) From differentiating metabolites to biomarkers. Anal Bioanal Chem 394:663–670PubMedCrossRef Koulman A, Lane GA, Harrison SJ (2009) From differentiating metabolites to biomarkers. Anal Bioanal Chem 394:663–670PubMedCrossRef
9.
go back to reference Lewis GD, Asnani A, Gerszten RE (2008) Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol 52:117–123PubMedCrossRef Lewis GD, Asnani A, Gerszten RE (2008) Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol 52:117–123PubMedCrossRef
10.
go back to reference National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266CrossRef National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1–S266CrossRef
11.
go back to reference Xu F, Zou L, Ong CN (2010) Experiment-oriented variations, multi-peak and multi-origination phenomena in derivatization-based GC-MS metabolomics. Trends Anal Chem 29:269–275CrossRef Xu F, Zou L, Ong CN (2010) Experiment-oriented variations, multi-peak and multi-origination phenomena in derivatization-based GC-MS metabolomics. Trends Anal Chem 29:269–275CrossRef
12.
go back to reference Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in multiple testing under dependency. Ann Stat 29:1165–1188CrossRef Benjamini Y, Yekutieli D (2001) The control of the false discovery rate in multiple testing under dependency. Ann Stat 29:1165–1188CrossRef
13.
go back to reference Tibshirani R (1997) The lasso method for variable selection in the Cox model. Stat Med 16:385–395PubMedCrossRef Tibshirani R (1997) The lasso method for variable selection in the Cox model. Stat Med 16:385–395PubMedCrossRef
15.
go back to reference Wills MR (1985) Uremic toxins, and their effect on intermediary metabolism. Clin Chem 31:5–13PubMed Wills MR (1985) Uremic toxins, and their effect on intermediary metabolism. Clin Chem 31:5–13PubMed
16.
go back to reference Mydlík M, Derzsiová K (2010) Vitamin B6 and oxalic acid in clinical nephrology. J Ren Nutr 20:S95–S102PubMedCrossRef Mydlík M, Derzsiová K (2010) Vitamin B6 and oxalic acid in clinical nephrology. J Ren Nutr 20:S95–S102PubMedCrossRef
18.
go back to reference Gillen DL, Worcester EM, Coe FL (2005) Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int 67:685–690PubMedCrossRef Gillen DL, Worcester EM, Coe FL (2005) Decreased renal function among adults with a history of nephrolithiasis: a study of NHANES III. Kidney Int 67:685–690PubMedCrossRef
20.
go back to reference Karasawa R, Nishi S, Suzuki Y, Imai N, Arakawa M (1997) Early increase of chondroitin sulphate glycosaminoglycan in the basement membrane of rats with diabetic glomerulopathy. Nephron 76:62–71PubMedCrossRef Karasawa R, Nishi S, Suzuki Y, Imai N, Arakawa M (1997) Early increase of chondroitin sulphate glycosaminoglycan in the basement membrane of rats with diabetic glomerulopathy. Nephron 76:62–71PubMedCrossRef
21.
go back to reference McCarthy KJ, Abrahamson DR, Bynum KR, St John PL, Couchman JR (1994) Basement membrane-specific chondroitin sulphate proteopglycan is abnormally associated with the glomerular capillary basement membrane of diabetic rats. J Histochem Cytochem 42:473–484PubMedCrossRef McCarthy KJ, Abrahamson DR, Bynum KR, St John PL, Couchman JR (1994) Basement membrane-specific chondroitin sulphate proteopglycan is abnormally associated with the glomerular capillary basement membrane of diabetic rats. J Histochem Cytochem 42:473–484PubMedCrossRef
22.
go back to reference Cadaval RAM, Kohlman O, Michelacci YM (2000) Urinary excretion of glycosaminoglycans and albumin in experimental diabetes mellitus. Glycobiology 10:185–192PubMedCrossRef Cadaval RAM, Kohlman O, Michelacci YM (2000) Urinary excretion of glycosaminoglycans and albumin in experimental diabetes mellitus. Glycobiology 10:185–192PubMedCrossRef
23.
go back to reference De Muro P, Fresu P, Tonolo G et al (2006) A longitudinal evaluation of urinary glycosaminoglycan excretion in normoalbuminuric type 1 diabetic patients. Clin Chem Lab Med 44:561–567PubMedCrossRef De Muro P, Fresu P, Tonolo G et al (2006) A longitudinal evaluation of urinary glycosaminoglycan excretion in normoalbuminuric type 1 diabetic patients. Clin Chem Lab Med 44:561–567PubMedCrossRef
24.
go back to reference De Muro P, Fresu P, Formato M et al (2002) Urinary glycosaminoglycan and proteoglycan excretion in normoalbumuric patients with type 1 diabetes mellitus. J Nephrol 15:290–296PubMed De Muro P, Fresu P, Formato M et al (2002) Urinary glycosaminoglycan and proteoglycan excretion in normoalbumuric patients with type 1 diabetes mellitus. J Nephrol 15:290–296PubMed
25.
go back to reference Martin DR, Lewington AJP, Hammerman MR, Padanilam BJ (2000) Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats. Am J Physiol Regul Integr Comp Physiol 279:R1834–R1840PubMed Martin DR, Lewington AJP, Hammerman MR, Padanilam BJ (2000) Inhibition of poly(ADP-ribose) polymerase attenuates ischemic renal injury in rats. Am J Physiol Regul Integr Comp Physiol 279:R1834–R1840PubMed
26.
go back to reference Banasik M, Komura H, Shimoyama M, Ueda K (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267:1569–1575PubMed Banasik M, Komura H, Shimoyama M, Ueda K (1992) Specific inhibitors of poly(ADP-ribose) synthetase and mono(ADP-ribosyl)transferase. J Biol Chem 267:1569–1575PubMed
27.
go back to reference Soriano FG, Virag L, Jagtap P et al (2001) Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108–113CrossRef Soriano FG, Virag L, Jagtap P et al (2001) Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 7:108–113CrossRef
28.
go back to reference Shevalye H, Stavniichuk R, Xu W et al (2010) Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. Biochem Pharmacol 79:1007–1014PubMedCrossRef Shevalye H, Stavniichuk R, Xu W et al (2010) Poly(ADP-ribose) polymerase (PARP) inhibition counteracts multiple manifestations of kidney disease in long-term streptozotocin-diabetic rat model. Biochem Pharmacol 79:1007–1014PubMedCrossRef
29.
go back to reference Szabó C, Biser A, Benko R, Böttinger E, Suszták K (2006) Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Lepr db/db mice. Diabetes 55:3004–3012PubMedCrossRef Szabó C, Biser A, Benko R, Böttinger E, Suszták K (2006) Poly(ADP-ribose) polymerase inhibitors ameliorate nephropathy of type 2 diabetic Lepr db/db mice. Diabetes 55:3004–3012PubMedCrossRef
30.
go back to reference Shevalye H, Maksimchyk Y, Watcho P, Obrosova IG (2010) Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic nephropathy. Biochim Biophys Acta 1802:1020–1027PubMed Shevalye H, Maksimchyk Y, Watcho P, Obrosova IG (2010) Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic nephropathy. Biochim Biophys Acta 1802:1020–1027PubMed
31.
go back to reference Zhao X, Fritsche J, Wang J et al (2010) Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 6:362–374PubMedCrossRef Zhao X, Fritsche J, Wang J et al (2010) Metabonomic fingerprints of fasting plasma and spot urine reveal human pre-diabetic metabolic traits. Metabolomics 6:362–374PubMedCrossRef
32.
go back to reference Cai S, Huo T, Xu J, Lui X, Zheng S, Li F (2009) Effect of mitiglinide on streptozotocin-induced experimental type 2 diabetic rats: a urinary metabonomics study based on ultra-performance liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:3619–3624PubMedCrossRef Cai S, Huo T, Xu J, Lui X, Zheng S, Li F (2009) Effect of mitiglinide on streptozotocin-induced experimental type 2 diabetic rats: a urinary metabonomics study based on ultra-performance liquid chromatography–tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:3619–3624PubMedCrossRef
33.
go back to reference Zhao LC, Zhang XD, Liao SX, Gao HC, Wang HY, Lin DH (2010) A metabonomic comparison of urinary changes in Zucker and GK rats. J Biomed Biotechnol 2010:431894. Zhao LC, Zhang XD, Liao SX, Gao HC, Wang HY, Lin DH (2010) A metabonomic comparison of urinary changes in Zucker and GK rats. J Biomed Biotechnol 2010:431894.
34.
go back to reference Zhao LC, Liu X, Xie L, Gao H, Lin D (2010) 1H NMR-based metabonomic analyses of metabolic changes in streptozotocin-induced diabetic rats. Anal Sci 26:1277–1282PubMedCrossRef Zhao LC, Liu X, Xie L, Gao H, Lin D (2010) 1H NMR-based metabonomic analyses of metabolic changes in streptozotocin-induced diabetic rats. Anal Sci 26:1277–1282PubMedCrossRef
35.
go back to reference Patterson AD, Bonzo JA, Li F et al (2011) Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 286:19511–19522PubMedCrossRef Patterson AD, Bonzo JA, Li F et al (2011) Metabolomics reveals attenuation of the SLC6A20 kidney transporter in nonhuman primate and mouse models of type 2 diabetes mellitus. J Biol Chem 286:19511–19522PubMedCrossRef
Metadata
Title
A metabolomic study of low estimated GFR in non-proteinuric type 2 diabetes mellitus
Authors
D. P. K. Ng
A. Salim
Y. Liu
L. Zou
F. G. Xu
S. Huang
H. Leong
C. N. Ong
Publication date
01-02-2012
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2012
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-011-2339-6

Other articles of this Issue 2/2012

Diabetologia 2/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.